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Background: The ECL2 of family B GPCRs has been suggested to contribute to biological activity.
Results:Mutation of most ECL2 residues to alanine results in changes in binding and/or efficacy of GLP-1 peptide agonists.
Conclusion: The ECL2 of the GLP-1R is critical for GLP-1 peptide-mediated receptor activation and selective signaling.
Significance: This work reveals broad significance for ECL2 in maintaining receptor conformations driving selective signaling.
The glucagon-like peptide-1 receptor (GLP-1R) is a therapeu-
tically important family B G protein-coupled receptor (GPCR)
that is pleiotropically coupled to multiple signaling effectors
and, with actions including regulation of insulin biosynthesis
and secretion, is one of the key targets in the management of
type II diabetes mellitus. However, there is limited understand-
ing of the role of the receptor core in orthosteric ligand binding
and biological activity. To assess involvement of the extracellu-
lar loop (ECL) 2 in ligand-receptor interactions and receptor
activation, we performed alanine scanning mutagenesis of loop
residues and assessed the impact on receptor expression and
GLP-1(1–36)-NH2 or GLP-1(7–36)-NH2 binding and activation
of three physiologically relevant signaling pathways as follows:
cAMP formation, intracellular Ca2 (Ca2i) mobilization, and
phosphorylation of extracellular signal-regulated kinases 1 and
2 (pERK1/2). Although antagonist peptide binding was unal-
tered, almost allmutations affectedGLP-1peptide agonist bind-
ing and/or coupling efficacy, indicating an important role in
receptor activation. However, mutation of several residues dis-
played distinct pathway responses with respect to wild type
receptor, including Arg-299 and Tyr-305, where mutation sig-
nificantly enhancedbothGLP-1(1–36)-NH2- andGLP-1(7–36)-
NH2-mediated signaling bias for pERK1/2. In addition, muta-
tion of Cys-296, Trp-297, Asn-300, Asn-302, and Leu-307
significantly increased GLP-1(7–36)-NH2-mediated signaling
bias toward pERK1/2. Of all mutants studied, only mutation of
Trp-306 to alanine abolished all biological activity. These data
suggest a critical role of ECL2 of the GLP-1R in the activation
transition(s) of the receptor and the importance of this region in
the determination of bothGLP-1 peptide- and pathway-specific
effects.
GPCRs3 are the largest family of transmembrane (TM)-span-
ning proteins, accounting for 1% of the human genome, and
are the leading target of marketed therapeutics (1, 2). Family B
peptide hormone receptors are a small subfamily ofGPCRs that
include receptors for secretin, calcitonin, vasoactive intestinal
polypeptide, pituitary adenylate cyclase-activating polypeptide,
corticotrophin-releasing factor, parathyroid hormone, gastric
inhibitory polypeptide, glucagon, and glucagon-like peptides
(GLPs). Each receptor possesses a characteristically large and
sequence-divergent extracellularN-terminal domain; however,
there is conservation of key residues, including three disulfide
bonds within this domain, that aids in stability and confers sim-
ilarities in secondary structure (3, 4). The widely accepted pep-
tide-receptor binding model for family B GPCRs is the two
domainmodel, whereby the -helical C terminus of the endog-
enous ligand interacts with the N-terminal domain of the
receptor, and the N terminus of the peptide interacts with the
core domain of the receptor, which includes both the extracel-
lular loops and TM bundle (5–7). Generically, the N-terminal
domain of the receptor is primarily responsible for ligand rec-
ognition and specificity, whereas the core of the receptor has a
major influence in signaling specificity and transmission (8).
Indeed, there is evidence through generation of both chimeric
receptors and peptides to suggest that this is true for many
family B receptors (9–16). However, there is also evidence that
ligand recognition and affinity determination can rely on inter-
action with the receptor core (14, 17–24); this is particularly
evident with the glucagon receptor, where changes in the N
terminus of the glucagon peptide significantly alter its binding
affinity at the glucagon receptor (17, 25, 26). In addition, sub-
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stitution of many N-terminal residues of the GLP-1, vasoactive
intestinal polypeptide, and secretin peptides for alanine signif-
icantly reduce binding affinity at the GLP-1R, VPAC receptors,
and secretin receptor, respectively (21, 23, 24), illustrating that
effective ligand recognition, binding, and subsequent biological
activity require the entire length of peptide and involve multi-
ple domains within the receptor.
Although crystal andNMR structures have been resolved for
the isolated N terminus of several ligand-bound family B
GPCRs, including the gastric inhibitory polypeptide receptor
(27), corticotrophin-releasing factor receptors (28–30), para-
thyroid hormone 1 receptor (31), and GLP-1 R (32, 33), only
limited mutagenesis and photoaffinity labeling data are avail-
able to aid in understanding the role of core domain residues.
Nevertheless, the data available highlight the significance of the
receptor core region in both peptide binding and receptor acti-
vation (34, 35), including residues within the putative ECL2 of
the GLP-1R (36, 37), secretin receptor (18), corticotrophin-re-
leasing factor receptors (38, 39), and parathyroid hormone
receptors (16), suggesting this potentially forms a significant
site of interaction for theN-terminal amino acids of the peptide
ligands and/or plays an important role in stabilizing active state
conformations in the presence of ligand.
LikemostGPCRs, family B receptors are promiscuously cou-
pled, including pathway coupling that leads to cAMP signaling,
Ca2i mobilization, and pERK1/2, each of which is linked to
important physiological functions of the receptors (40–42).
The relative activation of these signaling pathways may there-
fore be important for optimal development of therapeutics.
Nonetheless, our mechanistic understanding of how family B
receptors activate these distinct pathways is limited.
In this study, we explore the influence of individual ECL2
residues on humanGLP-1R function. TheGLP-1R is an impor-
tant target in the development of therapeutics for type II
diabetes mellitus, with actions including glucose-dependent
increases in insulin biosynthesis and secretion, increasing
-cell mass, and decreasing body mass, all effects that address
major symptoms of type II diabetes mellitus (43). Despite its
therapeutic promise, relatively limited data are available on the
contribution of domains in the receptor core on ligand binding
and receptor activation.We have performed systematic substi-
tution of each residue of ECL2 of the humanGLP-1R by alanine
and assessed the effects across a series of pharmacological out-
puts, which demonstrated critical residues for receptor activa-
tion that vary in an agonist peptide- or pathway-specific
manner.
EXPERIMENTAL PROCEDURES
Materials—Dulbecco’s modified Eagle’s medium (DMEM),
hygromycin-B, and Fluo-4 acetoxymethyl ester were purchased
from Invitrogen. Fetal bovine serum (FBS) was purchased from
Thermo Fisher Scientific (Melbourne, Victoria, Australia). The
QuikChangeTM site-directed mutagenesis kit was purchased
from Stratagene (La Jolla, CA). AlphaScreenTM reagents,
Bolton-Hunter reagent (125I), and 384-well ProxiPlates were
purchased from PerkinElmer Life Sciences. SureFireTM
ERK1/2 reagents were generously supplied by TGRBiosciences
(Adelaide, South Australia, Australia). SigmaFast o-phenylene-
diamine dihydrochloride tablets and antibodies were pur-
chased from Sigma. GLP-1 peptides were purchased from
American Peptide (Sunnyvale, CA). All other reagents were
purchased from Sigma or Merck and were of an analytical
grade.
Receptor Mutagenesis—To study the influence of specific
amino acids of ECL2 on receptor function, the desired muta-
tions were introduced to an N-terminally double c-Myc-la-
beled wild type human GLP-1R in the pEF5/FRT/V5-DEST
destination vector (Invitrogen); this receptor had equivalent
pharmacology to the untagged human GLP-1R (data not
shown). Mutagenesis was carried out using oligonucleotides
for site-directed mutagenesis from GeneWorks (Hind-
Marsh, South Australia, Australia) (supplemental Table S1)
and the QuikChangeTM site-directed mutagenesis kit (Strat-
agene). Sequences of receptor clones were confirmed by cycle
sequencing as described previously (44). Mutated residues and
their conservation across human family B peptide hormone
receptors are illustrated in Fig. 1.
Transfections and Cell Culture—Wild type and mutant
human GLP-1R were isogenically integrated into FlpIn-Chi-
nese hamster ovary (FlpInCHO) cells (Invitrogen) and selection
of receptor-expressing cells accomplished by treatment with
600gml1 hygromycin-B as described previously (44). Trans-
fected and parental FlpInCHOcells weremaintained inDMEM
supplemented with 10% heat-inactivated FBS and incubated in
a humidified environment at 37 °C in 5% CO2.
Radioligand Binding Assay—FlpInCHO wild type and
mutant humanGLP-1R cells were seeded at a density of 3 104
cells/well into 96-well culture plates and incubated overnight at
37 °C in 5% CO2, and radioligand binding was carried out as
described previously (45). For each cell line in all experiments,
total binding was defined by 0.5 nM 125I-exendin(9–39) alone,
and nonspecific binding was defined by 1 M exendin(9–39).
For analysis, data are normalized to the B0 value for each indi-
vidual experiment.
cAMP Accumulation Assay—FlpInCHO wild type and
mutant humanGLP-1R cells were seeded at a density of 3 104
cells/well into 96-well culture plates and incubated overnight at
37 °C in 5% CO2, and cAMP detection was carried out as
described previously (46). All values were converted to concen-
tration of cAMP using a cAMP standard curve performed in
parallel, and data were subsequently normalized to the
response of 100 M forskolin in each cell line.
pERK1/2 Assay—FlpInCHO wild type and mutant human
GLP-1R cells were seeded at a density of 3 104 cells/well into
96-well culture plates and incubated overnight at 37 °C in 5%
CO2. Receptor-mediated pERK1/2 was determined using the
AlphaScreenTM ERK1/2 SureFireTM protocol as described pre-
viously (44). Initial pERK1/2 time course experimentswere per-
formed over 1 h to determine the time at which agonist-medi-
ated pERK1/2 was maximal. Subsequent experiments were
then performed at the time required to generate a maximal
pERK1/2 response (6 min). Data were normalized to the maxi-
mal response elicited by 10%FBS in each cell line, determined at
6 min (peak FBS response).
Ca2i Mobilization Assay—FlpInCHOwild type andmutant
human GLP-1R cells were seeded at a density of 3 104 cells/
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well into 96-well culture plates and incubated overnight at
37 °C in 5% CO2, and receptor-mediated Ca2i mobilization
was determined as described previously (47). Fluorescence was
determined immediately after peptide addition, with an excita-
tion wavelength set to 485 nm and an emission wavelength set
to 520 nm, and readings were taken every 1.36 s for 120 s. Peak
magnitudewas calculated using five-point smoothing, followed
by correction against basal fluorescence. The peak value was
used to create concentration-response curves. Data were nor-
malized to the maximal response elicited by 100 M ATP.
Cell Surface Receptor Expression—FlpInCHO wild type and
mutant human GLP-1R cells, with receptor DNA previously
incorporated with an N-terminal double c-Myc epitope label,
were seeded at a density of 25  104 cells/well into 24-well
culture plates and incubated overnight at 37 °C in 5% CO2,
washed three times in 1 PBS, and fixed with 3.7% paraformal-
dehyde at 4 °C for 15 min. Cell surface receptor detection was
then performed as described previously (45). Data were nor-
malized to the basal fluorescence detected in FlpInCHOparen-
tal cells. Specific 125I-exendin(9–39) binding at each receptor
mutant, as identification of functional receptors at the cell sur-
face, was also determined (corrected for nonspecific binding
using 1 M exendin(9–39)).
Data Analysis—All data were analyzed using Prism 5.04
(GraphPad Software Inc., San Diego). For all analyses the data
are unweighted, and each y value (mean of replicates for each
individual experiment) is considered an individual point. Con-
centration response signaling data were analyzed using a three-
parameter logistic equation as described previously (44) and as
shown in Equation 1,
Y  Bottom
(Top Bottom)
1 10(log EC50 log[A])
(Eq. 1)
where Bottom represents the y value in the absence of ligand(s);
Top represents the maximal stimulation in the presence of
ligand(s); [A] is the molar concentration of ligand, and EC50
represents the molar concentration of ligand required to gen-
erate a response halfway between Top and Bottom. Similarly,
Equation 1 was used in the analysis of inhibition binding data,
instead replacing EC50 with IC50. In this case, Bottom defines
the specific binding of the radioligand that is equivalent to non-
specific ligand binding, whereas Top defines radioligand bind-
ing in the absence of a competing ligand, and the IC50 value
represents the molar concentration of ligand required to gen-
erate a response halfway between Top and Bottom. IC50 values
obtained were then corrected for radioligand occupancy as
described previously (48) using the radioligand affinity (Ki)
experimentally determined for each mutant.
To quantify efficacy in the system, all data were fitted with an
operational model of agonism (49) as shown in Equation 2,
Y  Bottom
Em Bottom
1 10logKA 10log[A]/10log  log[A]
(Eq. 2)
where Bottom represents the y value in the absence of ligand(s);
Em represents the maximal stimulation of the system; KA is the
agonist-receptor dissociation constant, inmolar concentration;
[A] is themolar concentration of ligand, and  is the operational
measure of efficacy in the system, which incorporates signaling
efficacy and receptor density. Constraints for this model were
determined by fitting the operationalmodel for a partial agonist
to each of the peptides at the wild type receptor, with the most
efficacious peptide fitted with Equation 3,
Y  Bottom
Em Bottom
1 10(log EC50 logA)
(Eq. 3)
and the less efficacious peptides were fitted with Equation 2, to
obtain a value for the system maximum (Em) at the wild type
receptor. This value was then globally constrained in the oper-
ational model (Equation 2) when applied at each of the mutant
receptors. All estimated  values were then corrected to cell
surface expression (c) as determined by specific 125I-
exendin(9–39) binding, and errors were propagated from both
 and cell surface expression. Changes in cwith respect to wild
type for each mutant were used to generate correlation plots,
which were subsequently fitted with linear regression and out-
liers established at greater than three standard deviations from
regression.
To quantify signaling bias, peptide agonist concentration-
response curves were analyzed with nonlinear regression using
an operational model of agonism (50), but modified to directly
estimate the ratio of c/KA, in amanner similar to that described
by Figueroa et al. (51). For each pathway, as shown in Equation
4,
Y 
Emax c/KA
n An
An c/KA
n 1 A/KA
n (Eq. 4)
the parameters are as defined for Equation 2. All estimated
c/KA ratios included propagation of error for both c and KA.
Changes in c/KA ratioswith respect towild type of eachmutant
were used to quantitate bias between signaling pathways.
Accordingly, bias factors included propagation of error from
c/KA ratios of each pathway.
Data were also normalized to maximal agonist response at
the wild type receptor in each signaling pathway, fitted with
a three-parameter logistic equation, and equimolar concentra-
tions of agonists in each pathway plotted against one other. In
this way, the bias of any given agonist for one pathway over
another can be visualized (50). In all cases, individual data sets
were unweighted during the analyses.
Statistics—Changes in peptide affinity, potency, efficacy, and
cell surface expression of ECL2 mutants in comparison with
wild type control were statistically analyzed with one-way anal-
ysis of variance and Dunnett’s post test, and significance was
accepted at p	 0.05.
RESULTS
Cell Surface Expression of HumanGLP-1R ECL2 Alanine
Mutants
Wild type c-Myc human GLP-1R and each of the human
GLP-1R ECL2 alanine mutants (Fig. 1A) were isogenically inte-
grated into FlpInCHOhost cells by recombination, allowing the
GLP-1R ECL2 Is Critical for Receptor Activation
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comparison of cell surface expression by antibody detection of
the N-terminal double c-Myc epitope label without complica-
tions arising fromvariations in gene transcription. In this study,
we observed total abolishment of cell surface receptor expres-
sion of the W306A mutant (Fig. 2A and Table 1). Significant
increases in cell surface receptor antibody labeling were
observed for the N300A and M303A mutants, although
decreases were observed for D293A, C296A, W297A, S301A,
N304A, Y305A, and L307A. No other mutant deviated signifi-
cantly in cell surface receptor antibody labeling in comparison
with wild type, although there were occasional trends for
increases or decreases. Inmost cases, the changes in cell surface
expression identified through antibody detection of the epitope
label were consistent with the pattern of specific binding of
125I-exendin(9–39) at each of the mutant receptors in compar-
ison with wild type receptor, although generically the 125I-
exendin(9–39) binding trended lower for the mutants relative
to the wild type, when compared with receptor antibody
labeling (Fig. 2B and Table 1). Notable exceptions to this were
E294A and T298A that demonstrated increased 125I-
exendin(9–39) binding but wild type levels of receptor anti-
body labeling and Y305A that displayed wild type levels of 125I-
exendin(9–39) binding and reduced antibody labeling. At each
of these receptormutants, the affinity of exendin(9–39) (deter-
mined through homologous competition binding) was not sig-
nificantly different from the wild type receptor (Table 1). As
exendin(9–39) affinity was unaltered at all mutant receptors,
reductions in 125I-exendin(9–39) binding but not antibody
labelingmay suggest a subpopulation of receptors forwhich the
ligand binding domain of the receptor is misfolded, leading to
loss of functional receptors at the cell surface. In these cases,
however, antibody detection of the inserted epitope tag does
not discriminate between different conformational states of the
ligand binding domain and therefore has most likely detected
all populations of receptor at the cell surface. The mechanism
underlying high 125I-exendin(9–39) in the absence of changes
to antibody labeling is less clear but may be due to altered con-
formation of the c-Myc epitope or an increase in the relative
proportion of receptors in an inactive state.
Select Mutants of the HumanGLP-1R ECL2 Influence GLP-1(7–
36)-NH2 Binding Affinity but Not Exendin(9–39) Affinity
To establish the binding profiles of each of the human
GLP-1R ECL2 alanine mutants, equilibrium binding studies
were performed with the endogenous peptide agonists GLP-
1(1–36)-NH2 and GLP-1(7–36)-NH2 in competition with the
radiolabeled orthosteric antagonist, 125I-exendin(9–39). There
was no significant deviation in antagonist exendin(9–39) affin-
ity at any of the mutated ECL2 residues, with the exception of
the W306A mutant, where no value could be defined as it was
undetectable at the cell surface (Table 1).
Full inhibition curves for the GLP-1(1–36)-NH2 peptide
could not be established over the concentration range tested; at
the highest concentration assayed (1 M), the level of binding
inhibition for most of the mutants was not significantly differ-
ent fromwild type receptor (Fig. 3,A and B). However, no clear
FIGURE 1.Amino acid sequence alignments.A, alignments of putative ECL2 of human family BGPCRs, with absolute conservation of residueswith respect to
human GLP-1R, are highlighted in boldface, and putative TM/ECL2 boundaries are indicated; B, human family B peptides, with absolute conservation of
residues with respect to human GLP-1 peptide, are highlighted in boldface.
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effect on bindingwas observed for C296A,W297A, R299A, and
Y305A (Fig. 3, A and B). This was likely a result of the poor
radioligand binding window for these mutants arising from the
low specific 125I-exendin(9–39) binding (Table 1).
There were no significant changes in affinity of GLP-1(7–
36)-NH2 in comparison with the wild type control for G285A,
I286A, V287A, Y289A, L290A, Y291A, E294A, G295A, T298A,
S301A, and N304A (Table 1). Decreases in binding affinity of
GLP-1(7–36)-NH2 in comparisonwithwild typewere observed
for K288A, E292A, D293A, R299A, N300A, N302A, M303A,
Y305A, and L307A mutants, as highlighted by gray shading in
Table 1 (Fig. 3, C and D, and Table 1).
Effect of HumanGLP-1R ECL2 AlanineMutations on
Peptide-mediated cAMP Accumulation
Binding Affinity-modified Mutants—There was no measura-
bleGLP-1(1–36)-NH2-mediated cAMP response at theK288A,
E292A, C296A, W297A or N300A mutants, and significant
depression in Emax was observed at the D293A, R299A, N302A,
M303A, Y305A, and L307A mutants (Fig. 4A and Table 2).
Application of the operational model indicated that each of
these mutant receptors had a significantly reduced coupling
efficiency for cAMP, after correction for functional cell surface
receptor levels (Fig. 4, A and E, and Table 2). Throughout the
results, the operational measure of efficacy (c) is used as the
principal measure of changes in efficacy for each pathway, as
this accounts for both alterations in coupling efficiency and cell
surface receptor expression (50).
All mutants displaying significantly decreased GLP-1(7–36)-
NH2 binding affinity (K288A, E292A, D293A, C296A, W297A,
R299A, N300A, N302A, M303A, Y305A, and L307A) also
exhibited reduced potency for cAMP in response to this pep-
tide, although this was not significant for the M303A mutant
(Fig. 4B and Table 2). Assessment of the effect on efficacy indi-
cated that all mutants also had diminished coupling efficiency
in addition to decreased affinity, although this effect was mini-
mal for D293A, C296A, and Y305A, where statistical signifi-
cance was not reached (Fig. 4, B and F, and Table 2). Not sur-
prisingly, cells expressing the W306A mutant did not respond
to peptide stimulation (Table 2).
Mutants with Unaltered Binding Affinity—For mutants that
were not affected at the level of peptide agonist binding,
potency was mostly unaltered with two exceptions as follows:
the V287A mutant, where decreased potency of GLP-1(7–36)-
NH2 was observed, and the T298A mutant that had increased
potency of GLP-1(7–36)-NH2 (Fig. 4D and Table 2). For the
latter, the increased potency was paralleled by higher expres-
sion of functional cell surface receptors (Fig. 1B) but was
accompanied by reduced efficacy (Fig. 4F and Table 2). Inter-
estingly, the loss of potency at the V287A mutant occurred in
the absence of significant changes in efficacy, for either the
FIGURE 2. Cell surface expression profiles of human GLP-1R ECL2 alanine mutants. Cell surface expression profiles of each of the human GLP-1R ECL2
alanine mutants are compared with wild type stably transfected into FlpInCHO cells as determined through antibody detection of the N-terminal c-Myc
epitope label (A) and by specific 125I-exendin(9–39) binding (B). Statistical significance of changes in total cell surface expression in comparisonwithwild type
human GLP-1R expression (100%) was determined by one-way analysis of variance and Dunnett’s post-test and are indicated with an asterisk (*, p	 0.05). All
data aremeans
S.E. of seven tonineor three to four independent experiments conducted induplicate for antibodydetection and specific 125I-exendin(9–39)
binding, respectively.
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full-length or truncated peptide. Overall, similar effects on effi-
cacy were observed for GLP-1(1–36)-NH2 and GLP-1(7–36)-
NH2 across the ECL2 mutants (Fig. 4, E and F, and Table 2).
G285A, I286A, V287A, and Y289A, located at the top of TM4/
proximal ECL2, had minimal effects on the efficacy of both
peptides. Similarly, therewas little effect on cAMPefficacywith
the G295Amutant. All other mutants displayed loss of efficacy
for both peptides, although the effect was not always significant
for both peptides. For example, there was a greater effect on
GLP-1(1–36)-NH2 efficacy with the L290A mutant and a
greater effect on GLP-1(7–36)-NH2 efficacy for the E294A,
T298A, and S301A mutants. For both peptides, the greatest
decrease in efficacy was seen with the N304Amutant (Table 2).
Effect of HumanGLP-1R ECL2 AlanineMutations on
Peptide-mediated pERK1/2
Binding Affinity-modified Mutants—Peptide-induced pERK1/
2was determined at 6min for each of the humanGLP-1R ECL2
alanine mutants. Consistent with cAMP accumulation, there
were no statistically significant differences in GLP-1(1–36)-
NH2 potency at these mutant receptors, although no measura-
ble response was seen for either N300A orW306A (Fig. 5A and
Table 3). In general, there was less impact of the ECL2mutants
on GLP-1(1–36)-NH2-mediated pERK1/2 signaling relative to
effects on cAMP response. Whereas the K288A, E292A,
C296A, W297A, and N300A all lacked measurable cAMP
responses in the presence of GLP-1(1–36)-NH2, only the
N300A mutant also failed to yield a pERK1/2 signal (Tables 2
and 3). Operational modeling of the effect of mutation on pep-
tide efficacy failed to identify any significant changes for these
mutants, althoughmost trended toward lower efficacy (Fig. 5,A
and E, and Table 3). The exception to this was R299A that
trended higher in efficacy for pERK1/2 (Table 3).
As with the GLP-1(1–36)-NH2 responses, there was gen-
erally less impact of ECL2 mutation on GLP-1(7–36)-NH2-
mediated pERK1/2 responses relative to the cAMP response
(Fig. 5B and Tables 2 and 3). Potency was largely unaffected
with only the K288A mutant exhibiting significantly lower
potency, although there was a trend toward lower potency
with some of the other affinity altered mutants, including
E292A and C296A (Fig. 5, B and F, and Table 3). The greatest
effects on GLP-1(7–36)-NH2 efficacy were seen with E292A
and N300A, the former being significantly lower (Fig. 5F and
Table 3). K288A, D293A, W297A, N302A, Y305A, and L307A
also trended toward lower efficacy. In contrast, C296A, R299A,
and M303A displayed higher efficacy than the wild type recep-
tor, although these effects did not reach significance. Interest-
ingly, the effect on coupling efficiency of GLP-1(1–36)-NH2
and GLP-1(7–36)-NH2 was opposite for C296A and M303A
suggesting that there are ligand-dependent effects imparted by
these mutations (Table 3). Intriguingly, the R299A mutant dis-
played consistent effects for the two peptides but distinct
effects in cAMP (decreased efficacy) versus pERK1/2 signaling
(increased efficacy), suggesting a pathway selective role for this
residue (Tables 2 and 3).
Mutants withUnaltered Binding Affinity—Overall, there was
only limited impact of ECL2 mutants on the pERK1/2
responses for mutant receptors that had unaltered agonist
binding affinity, and indeed, none of the effects achieved statis-
tical significance for eitherGLP-1(1–36)-NH2 orGLP-1(7–36)-
NH2 (Fig. 5, C and D, and Table 3). Nonetheless, there was
further distinction in the pattern of pERK1/2 efficacy changes
relative to Ca2i and cAMP signaling in that efficacy tended to
increase for many of the mutants, including G285A, I286A,
V287A, Y289A, G295A, and T298A in comparison with wild
type (Fig. 5, C–F, and Table 3). The L290A and Y291Amutants
tended to have decreased efficacy for the GLP-1(7–36)-NH2
peptide but had little effect on GLP-1(1–36)-NH2 responses. In
contrast, N304A had an apparent increase in efficacy for GLP-
1(1–36)-NH2 but unaltered GLP-1(7–36)-NH2 response
(Table 3).
Effect of HumanGLP-1R ECL2 AlanineMutations on
Peptide-mediated Ca2i Mobilization
Binding Affinity-modified Mutants—Consistent with previ-
ous data (46), there was no Ca2i response with full-length
TABLE 1
Effects of human GLP-1R ECL2 alanine mutants on peptide ligand
binding and cell surface expression
Binding data were analyzed using a three-parameter logistic equation as defined in
Equation 1 to obtain pIC50 values. pIC50 values were then corrected for radioligand
occupancy using the radioligand dissociation constant for each mutant, allowing
determination of ligand affinity (Ki). Data are normalized to maximum 125I-
exendin(9–39) binding in the absence of ligand, with nonspecific bindingmeasured
in the presence of 1 M exendin(9–39). For specific 125I-exendin(9–39) binding,
data are expressed as a maximum of specific 125I-exendin(9–39) binding at the wild
type human GLP-1R. Cell surface expression was determined through antibody
detection of theN-terminal c-Myc epitope label, with data expressed as amaximum
of wild type human GLP-1R expression. All values are expressed as means
 S.E. of
three to four (binding) or seven to nine (cell surface expression) independent exper-
iments, conducted in duplicate. Data were analyzed with one-way analysis of vari-
ance and Dunnett’s post test. Gray shading highlights residues effecting peptide
agonist binding affinity. ND means data were unable to be experimentally defined.
* Data are statistically significant at p	 0.05, one-way analysis of variance, and
Dunnett’s post test in comparison with wild type response.
** R2 values for the curve fits were all0.5, except for GLP-1(7–36)-NH2 at the
W297A (R2 0.42) and R299A (R2 0.46) mutants.
† GLP-1(1–36)-NH2 binding profile deviates from wild type, but the pIC50 value
for this ligand was unable to be determined in the concentration range tested.
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GLP-1 at either the wild type receptor or any of the alanine
mutants (data not shown).
Mutants that displayed reduced GLP-1(7–36)-NH2 binding
affinity (K288A, E292A, D293A, C296A, W297A, R299A,
N300A, N302A, M303A, Y305A, and L307A) displayed
either significantly reduced Ca2i signaling or complete loss
of signaling (Fig. 6A and Table 4). Notably, receptors with
abolished Ca2i signaling (K288A, E292A, C296A, W297A,
andN300A) were those that had the weakest ability to couple
to the cAMP pathway, with the exception of C296A (Table
2). In addition, these mutants also had weak coupling to the
pERK1/2 pathway, with the exception of C296A andW297A
(Table 3). Dramatic reductions in GLP-1(7–36)-NH2 effi-
cacy were observed at the remaining affinity-affectedmutant
receptors D293A, R299A, N302A, M303A, Y305A, and
L307A (Fig. 6, A and C, and Table 4). These decreases in
ability to couple to the Ca2i pathway were mostly reflected
in cAMP responses, although the extent of reductions in
efficacy was in some cases inconsistent; D293A and Y305A
were the most affected mutants in Ca2i but the least
affected in cAMP coupling in the presence of GLP-1(7–36)-
NH2 (Tables 2 and 4). Generically, the decreases in Ca2i
coupling were also reflected in pERK1/2 pathway coupling,
with the exception of R299A and M303A (Tables 3 and 4).
Mutants with Unaltered Binding Affinity—All mutants had
reduced GLP-1(7–36)-NH2 efficacy relative to the wild type
receptor, although the effect was not significant for G285A,
I286A, V287A, L290A, G295A, and S301A that were among the
least affected with respect to cAMP response (Fig. 6, B and C,
and Table 4). For nonbinding affected mutants, the greatest
effect on efficacy was observed with the N304A mutant, again
consistent with the magnitude of effect on cAMP signaling
(Tables 2 and 4).
Effect of HumanGLP-1R ECL2 AlanineMutations on
Peptide-mediated Signal Bias
As noted previously (46), GLP-1(1–36)-NH2 exhibits distinct
signal bias to that evoked by GLP-1(7–36)-NH2. GLP-1(7–36)-
NH2 is strongly biased toward cAMP formation relative to either
pERK1/2orCa2imobilization (supplemental Fig. S1,B andC). In
FIGURE 3. Agonist binding profiles of human GLP-1R ECL2 alanine mutants. Characterization of the binding of GLP-1(1–36)-NH2 (A and B) and GLP-1(7–
36)-NH2 (C andD) in competitionwith the radiolabeled antagonist,
125I-exendin(9–39), in whole FlpInCHO cells stably expressing thewild type humanGLP-1R
or each of the human GLP-1R ECL2 alaninemutants. Data are normalized tomaximum 125I-exendin(9–39) binding, with nonspecific bindingmeasured in the
presence of 1 M exendin(9–39) and analyzed with a three-parameter logistic equation as defined in Equation 1. All values are means
 S.E. of three to four
independent experiments, conducted in duplicate.
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contrast, GLP-1(1–36)-NH2 has equivalent preference for
cAMP and pERK1/2 (supplemental Fig. S1A). GLP-1(7–36)-
NH2, however, has only weak bias for the pERK1/2 pathway
relative to Ca2i mobilization (supplemental Fig. S1D). As
the GLP-1(1–36)-NH2 peptide did not elicit an Ca2i
response, relative bias against this pathway could not be
determined. Nonetheless, the absence of response is indica-
tive of bias toward cAMP and pERK1/2.
Bias plots provide a convenient visual representation of rel-
ative pathway response that is independent of absolute potency
(50), although bias factors are a quantitative measure of
changes to pathway bias, relative to the wild type receptor (50).
FIGURE 4. cAMP accumulation profiles of human GLP-1R ECL2 alanine mutants. Characterization of cAMP accumulation in the presence of GLP-1(1–36)-
NH2 (A and C) and GLP-1(7–36)-NH2 (B and D) in FlpInCHO cells stably expressing the wild type human GLP-1R or each of the human GLP-1R ECL2 alanine
mutants that effect peptide binding affinity (A and B) or has no significant effect on peptide binding affinity (C and D) is shown. Data are normalized to the
response elicited by 100M forskolin and analyzedwith an operationalmodel of agonism as defined in Equation 2. All values aremeans
 S.E. of four to seven
independent experiments, conducted in duplicate. Visual representation of cAMP pathway coupling efficacy (logc) in the presence of GLP-1(1–36)-NH2 (E)
GLP-1(7–36)-NH2 and (F) is shown. Statistical significance of changes in coupling efficacy in comparison with wild type human GLP-1R was determined by
one-way analysis of variance and Dunnett’s post-test and is indicated with an asterisk (*, p 	 0.05). All values are logc 
 S.E of four to seven independent
experiments, conducted in duplicate.
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Comparison of all mutants in this manner indicates that most
ECL2mutants engender at least subtle changes to receptor bias,
although residues Gly-285 and Ile-286 at the top of TM4 are
exceptions to this (supplemental Fig. S1). The G285Amutation
is interesting in that it engenders efficacy improvements for
cAMP and pERK1/2 responses and was minimally altered with
respect to Ca2i signaling. Themutants with themost dramatic
effects on relative signal biaswere also those thatwere altered in
binding affinity of GLP-1(7–36)-NH2, with the exception of
N304A, which consistently had a large differential effect across
pathways, and the T298A mutant that was among those
mutants with greatest effect on pERK1/2/cAMP for GLP-1(1–
36)-NH2 and for Ca2i/pERK1/2 for GLP-1(7–36)-NH2 (sup-
plemental Fig. S1, A and D), although the effect of these
mutants was not significant in bias factor calculations (Table 5).
Bias of cAMPor pERK1/2 relative toCa2iwas onlymoderately
affected by most mutants (supplemental Fig. S1, C and D); the
principal effect for Ca2i/cAMP for GLP-1(7–36)-NH2 was a
loss of efficacy for cAMP production rather than alteration to
bias per se, and this is reflected in the generally small changes to
bias factors for these pathways (Table 5). This is probably not
surprising as Ca2i is the weakest coupled pathway at the wild
type receptor, as discussed above. The greatest effects on bias
were seen with specific mutants on pERK1/2/cAMP profiles
(supplemental Fig. S1, A and B; Table 5). This was evident as
preservation of pERK1/2 response with near abolition of cAMP
response for R299A, N302A, N304A, and Y305A for GLP-1(1–
36)-NH2 and a complete reversal of bias for GLP-1(7–36)-NH2
such that pERK1/2was favored over cAMP forN300A,W297A,
C296A, and R299A. There was no clear bias for E292A, N302A,
N304A, and L307A, indicating loss of the cAMP bias seen with
the wild type receptor.
The effect of mutations to both increase and decrease effi-
cacy of ERK1/2 activation likely reflects the divergent pathways
that link receptor activation to pERK1/2, including both G pro-
tein-independent (52–55) and G protein-dependent mecha-
nisms (56). It is interesting to note that the most profound dif-
ferential effects on signaling occur with mutation to residues
distal to, or including, the conserved Cys-296/Trp-297 motif.
This segment of ECL2 is also the most important with respect
to binding of small molecule ligands into the TM region of
family A GPCRs (57–61).
TABLE 2
Effects of human GLP-1R ECL2 alanine mutants on peptide agonist signaling via cAMP
Data were analyzed using a three-parameter logistic equation as defined in Equation 1. pEC50 values represent the negative logarithm of the concentration of agonist that
produces half the maximal response. Emax represents the maximal response normalized to that elicited by 100 M forskolin. All mutants were analyzed with an operational
model of agonism (Equation 2) to determine log values. All log values were then corrected to specific 125I-exendin(9–39) binding (logc). Values are expressed as mean

S.E. of four to seven independent experiments, conducted in duplicate. Data were analyzed with one-way analysis of variance and Dunnett’s post test. Gray shading
highlights residues effecting peptide agonist binding affinity. ND means data were unable to be experimentally defined. R2 values for the global curve fits were 0.88 for
GLP-1(7–36)-NH2 and 0.92 for GLP-1(1–36)-NH2, respectively.
* Data were statistically significant at p	 0.05, one-way analysis of variance and Dunnett’s post test in comparison with the wild type response.
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DISCUSSION
It is widely accepted that the ECLs of family AGPCRs, particu-
larly ECL2, are an important component for receptor function,
with roles that include facilitating ligand binding, receptor traf-
ficking, communication of ligand signal, and/or stabilization of
an active ligand-receptor complex. Indeed, there is a plethora of
evidence formany of these features (62–66), including the acti-
vation of rhodopsin relying on the displacement of the -hair-
pin forming ECL2 via TM movement to allow ligand binding
(67), the design of antibodies against ECL2 of several GPCRs
that initiate a functional response (68, 69), and the substitution
of several domains in the ECL2 of the human gonadotropin-
releasing hormone receptor converting the activity of an antag-
onist to an agonist (70).
FIGURE 5. pERK1/2 profiles of human GLP-1R ECL2 alanine mutants. Characterization of pERK1/2 in the presence of GLP-1(1–36)-NH2 (A and C) and
GLP-1(7–36)-NH2 (B and D) in FlpInCHO cells stably expressing the wild type human GLP-1R or each of the human GLP-1R ECL2 alanine mutants that effect
peptide binding affinity (A and B) or has no significant effect on peptide binding affinity (C and D) is shown. Data are normalized to the maximal response
elicited by 10% FBS and analyzed with an operational model of agonism as defined in Equation 2. All values are means
 S.E. of five to seven independent
experiments, conducted in duplicate. Visual representationof ERK1/2 coupling efficacy (logc) in thepresence ofGLP-1(1–36)-NH2 (E) andGLP-1(7–36)-NH2 (F).
Statistical significance of changes in coupling efficacy in comparison with wild type human GLP-1R was determined by one-way analysis of variance and
Dunnett’s post-test and is indicated with an asterisk (*, p	 0.05). All values are logc
 S.E. five to seven independent experiments, conducted in duplicate.
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In this study we have used alanine scanning of ECL2 and
adjacent residues to probe the function of this domain of the
human GLP-1R. Virtually all mutations impacted on receptor
function, in particular on ligand efficacy, although the nature
and extent of effect varied considerably depending on the path-
way, the ligand, and the mutation. Collectively, the data are
indicative of a critical role for the GLP-1R ECL2 in the activa-
tion transition of the receptor. A global role for this domain in
activation transition is supported by analysis of efficacy changes
to mutants across the different pathways (Fig. 7). Although
there are exceptions (discussed below), there was generally a
good correlation between the magnitude of efficacy change for
the different pathways for individual mutants, although the
direction of change in the case of pERK1/2was not always in the
same direction as the other two pathways (that were almost
uniformly negative) (Fig. 7). The correlations suggest that the
mutations alter the ensemble of conformations formed/sam-
pled by the receptor in response to agonists; for a subset of
mutants there is greater propensity to form conformations
linked to activation of pERK1/2, but this is gained at the
expense of conformations linked to either cAMP formation or
Ca2i mobilization. The almost uniform loss of Ca2i efficacy
with individual mutations suggests that there is a high energy
barrier for formation of conformations allowing coupling to
this pathway, and this is consistent with the inability of GLP-
1(1–36)-NH2 to activate this pathway.
The recent solution of the crystal structure of the agonist-
bound 2-adrenergic receptor in complex with Gs (71) has
provided novel insight into the structural changes in the recep-
tor that accompany activation transition. This receptor under-
goes two major rearrangements on its intracellular face as fol-
lows: an outward displacement of TM6 by 14 Å and an
-helical extension of TM5. These changes open up the recep-
tor for interactionwith theGprotein. In the activated structure,
TABLE 3
Effects of human GLP-1R ECL2 alanine mutants on peptide agonist signaling via pERK1/2
Data were analyzed using a three-parameter logistic equation as defined in Equation 1. pEC50 values represent the negative logarithm of the concentration of agonist that
produces half the maximal response. Emax represents the maximal response normalized to that elicited by 10% FBS. All mutants were analyzed with an operational model
of agonism (Equation 2) to determine log values. All log values were then corrected to specific 125I-exendin(9–39) binding (logc). Values are expressed as means
 S.E.
of five to seven independent experiments, conducted in duplicate. Data were analyzed with one-way analysis of variance and Dunnett’s post test. R2 values for the global
curve fits were 0.68 for GLP-1(7–36)-NH2 and 0.57 for GLP-1(1–36)-NH2, respectively. Gray shading highlights residues effecting peptide agonist binding affinity. ND
means data were unable to be experimentally defined.
* Data were statistically significant at p	 0.05, one-way analysis of variance, and Dunnett’s post test in comparison with wild type response.
GLP-1R ECL2 Is Critical for Receptor Activation
3652 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 6•FEBRUARY 3, 2012
 at A
STO
N
 U
N
IV
ERSITY
 on Septem
ber 5, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
the 5 helix of Gs forms a network of polar interactions with
TM5, and therefore, the transmission of conformational
change to TM5 is likely to be very important for at least Gs
interactions. Our data are indicative of ECL2 playing a critical
role in the activation transition of the GLP-1R, potentially via
effects on the conformation of TM5. Consistent with this, there
was generally greater impact of mutation to residues that were
distal to the conserved Cys (Cys-296) that resides near the top
of TM5.
For all mutants expressed at the cell surface, binding of the
antagonist peptide exendin(9–39) was unaltered, and binding
affinity changes were restricted to the high affinity agonist pep-
tide GLP-1(7–36)-NH2 for a subset of mutants. The interpre-
tation of binding affinity changes for agonist peptides can be
difficult. Although agonists enable the transition of the recep-
tor to facilitate G protein binding, the ternary complex of the
receptor with the G protein (or indeed with other regulatory
proteins) provides thermodynamically reciprocal (allosteric)
regulation of agonist binding (72). This has been empirically
demonstrated for GPCRs using purified proteins, and for the
2-adrenoreceptor, it has been demonstrated that the full con-
formational alteration to the receptor requires both agonist and
G protein to be bound (73, 74). As such, major effects on recep-
tor-G protein interactions will manifest as selective loss of high
affinity agonist binding, such as those observed in this study,
and distinguishing direct effects on peptide binding from indi-
rect effects is problematic.
The most dramatic effects on receptor function were seen
with those mutants that also had reduced affinity for GLP-1(7–
36)-NH2. For the mutants with greatest loss of apparent affin-
ity, K288A, E292A, C296A, W297A, and N300A, there was a
corresponding major loss of receptor function, although the
loss of affinity alonewas insufficient to account for the extent of
functional loss. For theGLP-1(7–36)-NH2 peptide, thesemuta-
tions led to abolition of the Ca2i response and marked
decrease in potency for cAMP formation. For most mutants,
there was also a parallel loss in cAMP efficacy, and the excep-
tion to this was C296A, where efficacy was preserved (Tables
1–4). For GLP-1(1–36)-NH2 there was total loss of response in
cAMP formation. The effect on pERK1/2 was more complex.
Lys-288, Cys-296, and Trp-297 are each very highly conserved
across the B subfamily of peptide hormoneGPCRs and thismay
indicate a structural role for these residues (Fig. 1A). This is
supported by the loss of functional cell surface receptors seen
with alanine mutants of these residues (Table 1 and Fig. 2). For
Cys-296, a structural role is clearly evident with this amino acid
forming a disulfide bond with Cys-226 at the top of TM3; this
structural motif is highly conserved across the superfamily of
GPCRs and is evident in solved crystal structures for family A
GPCRs (57–61, 75, 76). In the rat GLP-1R, double mutation of
Cys-226 and Cys-296 to alanine restored the loss of GLP-1(7–
36)-NH2 binding affinity and cAMP signaling seen with indi-
vidual mutation of these residues, indicating that the disulfide
link itself is not required for efficient activation of the receptor
(77).
Recent photoaffinity cross-linking work has demonstrated
that Leu-20 of GLP-1(7–36)-NH2 is proximal to Trp-297 of the
receptor, with subsequent molecular modeling indicating that
it could form a direct interaction thatmay contribute to the loss
of function observed with mutation of this residue (36). Inter-
estingly, Leu-20 is distal to the segment of the GLP-1 peptide
(and indeed other related peptide hormones) that is linked to
agonistic activity. Dipeptidyl peptidase IV cleavage of the two
N-terminal residues markedly attenuates the activity of GLP-
1(7–36)-NH2, and truncation by six amino acids is sufficient to
abolish agonist activity (78). In this study binding affinity of the
antagonist peptide exendin(9–39) was unaltered by any of the
mutations, and thus it seems unlikely that the extent of loss of
function seen with theW297A is due to loss of a direct interac-
tion. It has been speculated that low binding affinity for GLP-
1(7–36)-NH2 for the isolated N-terminal extracellular domain
of the GLP-1R is due to decreased capacity of GLP-1(7–36)-
FIGURE 6. Ca2imobilization profiles of humanGLP-1R ECL2 alaninemutants. Characterization of Ca
2
imobilization in the presence of GLP-1(7–36)-NH2
in FlpInCHO cells stably expressing the wild type human GLP-1R or each of the human GLP-1R ECL2 alaninemutants that effect peptide binding affinity (A) or
has no significant effect on peptide binding affinity (B) is shown. Data are normalized to the maximal response elicited by 100 M ATP and analyzed with an
operational model of agonism as defined in Equation 2. All values are means
 S.E. of three to five independent experiments, conducted in duplicate. Visual
representation of Ca2i coupling efficacy (logc) in the presence of GLP-1(7–36)-NH2 (C) is shown. Statistical significance of changes in coupling efficacy in
comparison with wild type human GLP-1R was determined by one-way analysis of variance and Dunnett’s post-test and is indicated with an asterisk (*, p	
0.05). All values are logc
 S.E. of three to five independent experiments, conducted in duplicate.
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NH2 to form an extended -helix in the absence of the receptor
core (79). It is possible that one role of Trp-297 is to help stabi-
lize peptide secondary structure. Nonetheless, Trp-297 is com-
pletely conserved across all B familymembers suggesting that it
is structurally important.
Mutation of Lys-288 to alanine in the rat GLP-1R leads to a
similar decrease in GLP-1(7–36)-NH2 affinity to that observed
in this study, and although a cAMP response via the rat GLP-1R
is detectable, there is a marked decrease in potency. At the
equivalent position in other family B receptors, this amino acid
is highly conserved with an invariant basic residue (Arg or Lys)
present (Fig. 1A). Al-Sabah and Donnelly (37) have speculated
that Lys-288 likely resides at the border between TM4 and
ECL2 and that a basic residue in this position is potentially
required for important interactions with neighboring TM res-
idues. Nonetheless, such basic amino acids may also reside at
the hydrophobic face of TM helices and undergo what is
termed “snorkeling,” where the side chain is oriented parallel to
themembranehelix leading to stabilization of the top of theTM
helix (80), and this may be important in receptor function.
Glu-292 and Asn-300 are partially conserved across B family
receptors, being homologous with more closely related mem-
bers of the family (Fig. 1A). These receptors also have the great-
est degree of homology with the N-terminal sequences of their
activating peptides (Fig. 1B), and this may suggest more direct
importance for interaction between the receptors and peptides.
Although among themost deleterious ofmutations for all path-
ways, their effect on relative efficacy across pathways is consis-
tent with most other ECL2mutations (Fig. 7). Nonetheless, the
N300A mutant, like C296A and W297A, reversed GLP-1(7–
36)-NH2-mediated signal bias between pERK1/2 and cAMP
formation (supplemental Fig. S1B).
Of all themutants studied, onlyW306Awas not expressed at
the cell surface, indicating that themutation leads tomisfolding
of the receptor. Curiously, double mutation of Tyr-305 and
Trp-306 to alanine in the ratGLP-1R resulted in a population of
receptors that were cell surface-expressed and responded to
peptide agonists, albeit with marked effects on potency (77),
suggesting that either interspecies differences in receptor
sequence provide for greater stability of rat receptor structure
or that the additional mutation compensated for some of the
detrimental interactions arising from individual mutation of
Trp-306.
All of the other mutations that altered the affinity of GLP-
1(7–36)-NH2, D293A, R299A, N302A, M303A, Y305A, and
TABLE 4
Effects of human GLP-1R ECL2 alanine mutants on peptide agonist
signaling via Ca2imobilization
Datawere analyzed using a three-parameter logistic equation as defined in Equation
1. pEC50 values represent the negative logarithmof the concentration of agonist that
produces half themaximal response.Emax represents themaximal response normal-
ized to that elicited by 100 M ATP. All mutants were analyzed with an operational
model of agonism (Equation 2) to determine log values. All log values were then
corrected to specific 125I-exendin(9–39) binding (logc). Values are expressed as
means 
 S.E. of three to five independent experiments, conducted in duplicate.
Datawere analyzedwith one-way analysis of variance andDunnett’s post test TheR2
value for the global curve fit was 0.79. Gray shading highlights residues effecting
peptide agonist binding affinity. ND means data were unable to be experimentally
defined.
* Data were statistically significant at p	 0.05, one-way analysis of variance, and
Dunnett’s post test in comparison with wild type response.
TABLE 5
Effects of human GLP-1R ECL2 alanine mutants on peptide agonist-
mediated signaling bias
Data were analyzed using an operational model of agonism as defined in Equation 4
to estimate logc/KA ratios. Changes in logc/KA ratioswith respect towild typewere
used to quantitate bias between signaling pathways. Values are expressed as
means 
 S.E. of three to seven independent experiments, conducted in duplicate.
Data were analyzed with one-way analysis of variance and Dunnett’s post test. Gray
shading highlights residues effecting peptide agonist binding affinity. ND means
were data unable to be experimentally defined.
* Data were statistically significant at p	 0.05, one-way analysis of variance, and
Dunnett’s post test in comparison with wild type response.
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L307A were among those residues that conferred the largest
differential effects on either signal bias (supplemental Fig. S1)
or magnitude of change to efficacy across pathways (Fig. 7). Of
the other mutants within ECL2, which did not alter GLP-1(7–
36)-NH2 affinity, only N304A that is near the apex of TM5
caused significant differential effects across signaling pathways.
These data are indicative of a novel and important role for ECL2
in conferring the distinct conformations that underlie pathway
selective signaling. Whether this occurs purely through effects
on the conformation ofTM5orwhether additional interactions
of ECL2 residues with other loop regions are involved is
unclear.
FIGURE7.Correlationplots ofpathwayefficacy (logc) of humanGLP-1RECL2alaninemutants.Correlationplots of changes inpathway coupling efficacy
(logc) of human GLP-1R ECL2 alanine mutants with respect to wild type receptor are shown. A, cAMP versus pERK1/2 for GLP-1(1–36)-NH2; B, cAMP versus
pERK1/2 for GLP-1(7–36)-NH2; C, Ca
2
i versus cAMP for GLP-1(7–36)-NH2; D, Ca
2
i versus cAMP for GLP-1(7–36)-NH2 after exclusion of D293A and Y305A; and
E, pERK1/2 versus Ca2i for GLP-1(7–36)-NH2. Data were fit by linear regression. The line of regression and 99% confidence intervals are displayed.
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The two GLP-1 peptides used in this study differ only by a
six-amino acid extension to the GLP-1(7–36)-NH2 sequence.
Not surprisingly, most mutations had similar effects on
responses to both peptides. Nonetheless, GLP-1(1–36)-NH2
exhibits distinct signal bias to that demonstrated by GLP-1(7–
36)-NH2, indicating that it produces a different ensemble of
receptor conformations to that of the truncated peptide. Con-
sistent with the effects of the different peptides in altering
receptor bias, C296A, R299A, N302A, N304A, and Y305A had
differential effects on the truncated and full-length GLP-1 pep-
tides. Differential effects were also seen with the G285A
mutant. Both peptides displayed increased efficacy at this
mutant receptor; however, greater improvement in pERK1/2
efficacy was seen for GLP-1(1–36)-NH2 relative to GLP-1(7–
36)-NH2. Alanine at this position may thus provide some con-
formational restriction that allows the lower affinity full-length
peptide to more readily activate the pERK1/2 pathway com-
pared with the wild type receptor.
In conclusion, we have demonstrated a critical role for ECL2
in activation of the GLP-1R. However, the precise molecular
mechanisms driving these effects remain elusive in the absence
of high resolution structural information for family B GPCRs.
Our data point to a major role for ECL2 in activation transition
and that changes to structure in this receptor region can alter
pathway bias of the receptor that can bemanifested in a ligand-
specific manner.
REFERENCES
1. Harmar, A. J., Hills, R. A., Rosser, E. M., Jones, M., Buneman, O. P., Dun-
bar, D. R., Greenhill, S. D., Hale, V. A., Sharman, J. L., Bonner, T. I., Cat-
terall, W. A., Davenport, A. P., Delagrange, P., Dollery, C. T., Foord, S. M.,
Gutman, G. A., Laudet, V., Neubig, R. R., Ohlstein, E. H., Olsen, R. W.,
Peters, J., Pin, J. P., Ruffolo, R. R., Searls, D. B., Wright, M. W., and Sped-
ding, M. (2009) IUPHAR-DB. The IUPHAR database of G protein-cou-
pled receptors and ion channels. Nucleic Acids Res. 37, D680–D685
2. Overington, J. P., Al-Lazikani, B., and Hopkins, A. L. (2006) How many
drug targets are there? Nat. Rev. Drug Discov. 5, 993–996
3. Bazarsuren, A., Grauschopf, U., Wozny, M., Reusch, D., Hoffmann, E.,
Schaefer, W., Panzner, S., and Rudolph, R. (2002) In vitro folding, func-
tional characterization, and disulfide pattern of the extracellular domain
of human GLP-1 receptor. Biophys. Chem. 96, 305–318
4. Grauschopf, U., Lilie, H., Honold, K., Wozny, M., Reusch, D., Esswein, A.,
Scha¨fer, W., Ru¨cknagel, K. P., and Rudolph, R. (2000) The N-terminal
fragment of human parathyroid hormone receptor 1 constitutes a hor-
mone binding domain and reveals a distinct disulfide pattern. Biochemis-
try 39, 8878–8887
5. Bisello, A., Adams, A. E.,Mierke, D. F., Pellegrini,M., Rosenblatt,M., Suva,
L. J., and Chorev, M. (1998) Parathyroid hormone-receptor interactions
identified directly by photocross-linking and molecular modeling studies.
J. Biol. Chem. 273, 22498–22505
6. Dong, M., Li, Z., Pinon, D. I., Lybrand, T. P., andMiller, L. J. (2004) Spatial
approximation between the amino terminus of a peptide agonist and the
top of the sixth transmembrane segment of the secretin receptor. J. Biol.
Chem. 279, 2894–2903
7. Dong, M., Pinon, D. I., Cox, R. F., and Miller, L. J. (2004) Molecular ap-
proximation between a residue in the amino-terminal region of calcitonin
and the third extracellular loop of the class BG protein-coupled calcitonin
receptor. J. Biol. Chem. 279, 31177–31182
8. Hoare, S. R. (2005)Mechanisms of peptide and nonpeptide ligand binding
to Class B G-protein-coupled receptors.Drug Discov. Today 10, 417–427
9. Bergwitz, C., Gardella, T. J., Flannery, M. R., Potts, J. T., Jr., Kronenberg,
H. M., Goldring, S. R., and Ju¨ppner, H. (1996) Full activation of chimeric
receptors by hybrids between parathyroid hormone and calcitonin. Evi-
dence for a common pattern of ligand-receptor interaction. J. Biol. Chem.
271, 26469–26472
10. Graziano, M. P., Hey, P. J., and Strader, C. D. (1996) The amino-terminal
domain of the glucagon-like peptide-1 receptor is a critical determinant of
subtype specificity. Receptors Channels 4, 9–17
11. Holtmann, M. H., Hadac, E. M., and Miller, L. J. (1995) Critical contribu-
tions of amino-terminal extracellular domains in agonist binding and ac-
tivation of secretin and vasoactive intestinal polypeptide receptors. Stud-
ies of chimeric receptors. J. Biol. Chem. 270, 14394–14398
12. Wilmen, A., Go¨ke, B., and Go¨ke, R. (1996) The isolated N-terminal extra-
cellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has in-
trinsic binding activity. FEBS Lett. 398, 43–47
13. Wilmen, A., Van Eyll, B., Go¨ke, B., and Go¨ke, R. (1997) Five out of six
tryptophan residues in the N-terminal extracellular domain of the rat
GLP-1 receptor are essential for its ability to bind GLP-1. Peptides 18,
301–305
14. Gelling, R. W., Wheeler, M. B., Xue, J., Gyomorey, S., Nian, C., Pederson,
R. A., andMcIntosh, C. H. (1997) Localization of the domains involved in
ligand binding and activation of the glucose-dependent insulinotropic
polypeptide receptor. Endocrinology 138, 2640–2643
15. Castro, M., Nikolaev, V. O., Palm, D., Lohse, M. J., and Vilardaga, J. P.
(2005) Turn-on switch in parathyroid hormone receptor by a two-step
parathyroid hormone binding mechanism. Proc. Natl. Acad. Sci. U.S.A.
102, 16084–16089
16. Bergwitz, C., Jusseaume, S. A., Luck,M. D., Ju¨ppner, H., and Gardella, T. J.
(1997) Residues in themembrane-spanning and extracellular loop regions
of the parathyroid hormone (PTH)-2 receptor determine signaling selec-
tivity for PTH and PTH-related peptide. J. Biol. Chem. 272, 28861–28868
17. Hjorth, S. A., Adelhorst, K., Pedersen, B. B., Kirk, O., and Schwartz, T. W.
(1994) Glucagon and glucagon-like peptide 1. Selective receptor recogni-
tion via distinct peptide epitopes. J. Biol. Chem. 269, 30121–30124
18. Holtmann, M. H., Ganguli, S., Hadac, E. M., Dolu, V., and Miller, L. J.
(1996) Multiple extracellular loop domains contribute critical determi-
nants for agonist binding and activation of the secretin receptor. J. Biol.
Chem. 271, 14944–14949
19. Buggy, J. J., Livingston, J. N., Rabin, D. U., and Yoo-Warren, H. (1995)
Glucagonglucagon-like peptide I receptor chimeras reveal domains that
determine specificity of glucagon binding. J. Biol. Chem. 270, 7474–7478
20. Xiao, Q., Jeng, W., and Wheeler, M. B. (2000) Characterization of gluca-
gon-like peptide-1 receptor-binding determinants. J. Mol. Endocrinol. 25,
321–335
21. Adelhorst, K., Hedegaard, B. B., Knudsen, L. B., and Kirk, O. (1994) Struc-
ture-activity studies of glucagon-like peptide-1. J. Biol. Chem. 269,
6275–6278
22. Mojsov, S. (1992) Structural requirements for biological activity of gluca-
gon-like peptide-I. Int. J. Pept. Protein Res. 40, 333–343
23. Nicole, P., Lins, L., Rouyer-Fessard, C., Drouot, C., Fulcrand, P., Thomas,
A., Couvineau, A., Martinez, J., Brasseur, R., and Laburthe, M. (2000)
Identification of key residues for interaction of vasoactive intestinal pep-
tide with human VPAC1 and VPAC2 receptors and development of a
highly selective VPAC1 receptor agonist. Alanine scanning andmolecular
modeling of the peptide. J. Biol. Chem. 275, 24003–24012
24. Dong,M., Le, A., Te, J. A., Pinon,D. I., Bordner, A. J., andMiller, L. J. (2011)
Importance of each residue within secretin for receptor binding and bio-
logical activity. Biochemistry 50, 2983–2993
25. Runge, S., Wulff, B. S., Madsen, K., Bra¨uner-Osborne, H., and Knudsen,
L. B. (2003) Different domains of the glucagon and glucagon-like pep-
tide-1 receptors provide the critical determinants of ligand selectivity.
Br. J. Pharmacol. 138, 787–794
26. Runge, S., Gram, C., Brauner-Osborne, H., Madsen, K., Knudsen, L. B.,
andWulff, B. S. (2003) Three distinct epitopes on the extracellular face of
the glucagon receptor determine specificity for the glucagon amino ter-
minus. J. Biol. Chem. 278, 28005–28010
27. Parthier, C., Kleinschmidt, M., Neumann, P., Rudolph, R., Manhart, S.,
Schlenzig, D., Fangha¨nel, J., Rahfeld, J. U., Demuth, H. U., and Stubbs,
M. T. (2007) Crystal structure of the incretin-bound extracellular domain
of a G protein-coupled receptor. Proc. Natl. Acad. Sci. U.S.A. 104,
13942–13947
GLP-1R ECL2 Is Critical for Receptor Activation
3656 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 6•FEBRUARY 3, 2012
 at A
STO
N
 U
N
IV
ERSITY
 on Septem
ber 5, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
28. Grace, C. R., Perrin,M.H., DiGruccio,M. R.,Miller, C. L., Rivier, J. E., Vale,
W.W., and Riek, R. (2004) NMR structure and peptide hormone-binding
site of the first extracellular domain of a type B1 G protein-coupled recep-
tor. Proc. Natl. Acad. Sci. U.S.A. 101, 12836–12841
29. Grace, C. R., Perrin,M. H., Gulyas, J., Digruccio,M. R., Cantle, J. P., Rivier,
J. E., Vale, W.W., and Riek, R. (2007) Structure of the N-terminal domain
of a type B1 G protein-coupled receptor in complex with a peptide ligand.
Proc. Natl. Acad. Sci. U.S.A. 104, 4858–4863
30. Pioszak, A. A., Parker, N. R., Suino-Powell, K., and Xu, H. E. (2008) Mo-
lecular recognition of corticotropin-releasing factor by its G-protein-cou-
pled receptor CRFR1. J. Biol. Chem. 283, 32900–32912
31. Pioszak, A. A., and Xu, H. E. (2008) Molecular recognition of parathyroid
hormone by its G protein-coupled receptor. Proc. Natl. Acad. Sci. U.S.A.
105, 5034–5039
32. Runge, S., Thøgersen, H., Madsen, K., Lau, J., and Rudolph, R. (2008)
Crystal structure of the ligand-bound glucagon-like peptide-1 receptor
extracellular domain. J. Biol. Chem. 283, 11340–11347
33. Underwood, C. R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H.,
Rudolph, R., and Reedtz-Runge, S. (2010) Crystal structure of glucagon-
like peptide-1 in complex with the extracellular domain of the glucagon-
like peptide-1 receptor. J. Biol. Chem. 285, 723–730
34. Lo´pez de Maturana, R., and Donnelly, D. (2002) The glucagon-like pep-
tide-1 receptor binding site for the N-terminus of GLP-1 requires polarity
at Asp-198 rather than negative charge. FEBS Lett. 530, 244–248
35. Lo´pez de Maturana, R., Treece-Birch, J., Abidi, F., Findlay, J. B., and Don-
nelly, D. (2004) Met-204 and Tyr-205 are together important for binding
GLP-1 receptor agonists but not their N-terminally truncated analogues.
Protein Pept. Lett. 11, 15–22
36. Miller, L. J., Chen, Q., Lam, P. C., Pinon, D. I., Sexton, P. M., Abagyan, R.,
and Dong, M. (2011) Refinement of glucagon-like peptide 1 docking to its
intact receptor using mid-region photolabile probes and molecular mod-
eling. J. Biol. Chem. 286, 15895–15907
37. Al-Sabah, S., andDonnelly, D. (2003) The positive charge at Lys-288 of the
glucagon-like peptide-1 (GLP-1) receptor is important for binding the
N-terminus of peptide agonists. FEBS Lett. 553, 342–346
38. Assil-Kishawi, I., and Abou-Samra, A. B. (2002) Sauvagine cross-links to
the second extracellular loop of the corticotropin-releasing factor type 1
receptor. J. Biol. Chem. 277, 32558–32561
39. Liaw, C. W., Grigoriadis, D. E., Lovenberg, T. W., De Souza, E. B., and
Maki, R. A. (1997) Localization of ligand-binding domains of human cor-
ticotropin-releasing factor receptor. A chimeric receptor approach. Mol.
Endocrinol. 11, 980–985
40. Baggio, L. L., and Drucker, D. J. (2007) Biology of incretins. GLP-1 and
GIP. Gastroenterology 132, 2131–2157
41. Quoyer, J., Longuet, C., Broca, C., Linck, N., Costes, S., Varin, E., Bockaert,
J., Bertrand, G., and Dalle, S. (2010) GLP-1 mediates antiapoptotic effect
by phosphorylating Bad through a -arrestin 1-mediated ERK1/2 activa-
tion in pancreatic beta-cells. J. Biol. Chem. 285, 1989–2002
42. Klinger, S., Poussin, C., Debril, M. B., Dolci, W., Halban, P. A., and Tho-
rens, B. (2008) IncreasingGLP-1-induced beta-cell proliferation by silenc-
ing the negative regulators of signaling cAMP-response element modula-
tor- and DUSP14. Diabetes 57, 584–593
43. Drucker, D. J., and Nauck, M. A. (2006) The incretin system. Glucagon-
like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in
type 2 diabetes. Lancet 368, 1696–1705
44. May, L. T., Avlani, V. A., Langmead, C. J., Herdon, H. J., Wood, M. D.,
Sexton, P. M., and Christopoulos, A. (2007) Structure-function studies of
allosteric agonism at M2 muscarinic acetylcholine receptors. Mol. Phar-
macol. 72, 463–476
45. Koole, C., Wootten, D., Simms, J., Valant, C., Miller, L. J., Christopoulos,
A., and Sexton, P. M. (2011) Polymorphism and ligand-dependent
changes in human glucagon-like peptide-1 receptor (GLP-1R) function:
allosteric rescue of loss of function mutation. Mol. Pharmacol. 80,
486–497
46. Koole, C.,Wootten, D., Simms, J., Valant, C., Sridhar, R.,Woodman, O. L.,
Miller, L. J., Summers, R. J., Christopoulos, A., and Sexton, P. M. (2010)
Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differ-
entiallymodulate endogenous and exogenous peptide responses in a path-
way-selective manner: implications for drug screening. Mol. Pharmacol.
78, 456–465
47. Werry, T. D., Gregory, K. J., Sexton, P. M., and Christopoulos, A. (2005)
Characterization of serotonin 5-HT2C receptor signaling to extracellular
signal-regulated kinases 1 and 2. J. Neurochem. 93, 1603–1615
48. Cheng, Y., and Prusoff, W. H. (1973) Relationship between the inhibition
constant (K1) and the concentration of inhibitor which causes 50% inhi-
bition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–3108
49. Black, J. W., and Leff, P. (1983) Operational models of pharmacological
agonism. Proc. R. Soc. Lond. B Biol. Sci. 220, 141–162
50. Gregory, K. J., Hall, N. E., Tobin, A. B., Sexton, P.M., andChristopoulos, A.
(2010) Identification of orthosteric and allosteric site mutations in M2
muscarinic acetylcholine receptors that contribute to ligand-selective sig-
naling bias. J. Biol. Chem. 285, 7459–7474
51. Figueroa, K. W., Griffin, M. T., and Ehlert, F. J. (2009) Selectivity of ago-
nists for the active state of M1 to M4 muscarinic receptor subtypes.
J. Pharmacol. Exp. Ther. 328, 331–342
52. Luttrell, L. M., Ferguson, S. S., Daaka, Y., Miller,W. E., Maudsley, S., Della
Rocca,G. J., Lin, F., Kawakatsu,H.,Owada, K., Luttrell, D. K., Caron,M.G.,
and Lefkowitz, R. J. (1999) -Arrestin-dependent formation of 2-adre-
nergic receptor-Src protein kinase complexes. Science 283, 655–661
53. DeFea, K. A., Zalevsky, J., Thoma, M. S., De´ry, O., Mullins, R. D., and
Bunnett, N. W. (2000) -Arrestin-dependent endocytosis of proteinase-
activated receptor 2 is required for intracellular targeting of activated
ERK1/2. J. Cell Biol. 148, 1267–1281
54. Luttrell, L. M., Roudabush, F. L., Choy, E. W., Miller, W. E., Field, M. E.,
Pierce, K. L., and Lefkowitz, R. J. (2001) Activation and targeting of extra-
cellular signal-regulated kinases by -arrestin scaffolds. Proc. Natl. Acad.
Sci. U.S.A. 98, 2449–2454
55. Shenoy, S. K., Drake, M. T., Nelson, C. D., Houtz, D. A., Xiao, K., Mada-
bushi, S., Reiter, E., Premont, R. T., Lichtarge, O., and Lefkowitz, R. J.
(2006) -Arrestin-dependent, G protein-independent ERK1/2 activation
by the 2-adrenergic receptor. J. Biol. Chem. 281, 1261–1273
56. Pearson, G., Robinson, F., Beers Gibson, T., Xu, B. E., Karandikar, M.,
Berman, K., and Cobb, M. H. (2001) Mitogen-activated protein (MAP)
kinase pathways. Regulation and physiological functions. Endocr. Rev. 22,
153–183
57. Warne, T., Serrano-Vega, M. J., Baker, J. G., Moukhametzianov, R., Ed-
wards, P. C., Henderson, R., Leslie, A. G., Tate, C. G., and Schertler, G. F.
(2008) Structure of a 1-adrenergic G-protein-coupled receptor. Nature
454, 486–491
58. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A.,Motoshima, H., Fox,
B. A., Le Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto,
M., and Miyano, M. (2000) Crystal structure of rhodopsin. A G protein-
coupled receptor. Science 289, 739–745
59. Cherezov, V., Rosenbaum, D.M., Hanson,M. A., Rasmussen, S. G., Thian,
F. S., Kobilka, T. S., Choi, H. J., Kuhn, P., Weis, W. I., Kobilka, B. K., and
Stevens, R. C. (2007) High resolution crystal structure of an engineered
human 2-adrenergic G protein-coupled receptor. Science 318,
1258–1265
60. Chien, E. Y., Liu, W., Zhao, Q., Katritch, V., Han, G. W., Hanson, M. A.,
Shi, L., Newman, A. H., Javitch, J. A., Cherezov, V., and Stevens, R. C.
(2010) Structure of the human dopamine D3 receptor in complex with a
D2/D3 selective antagonist. Science 330, 1091–1095
61. Jaakola, V. P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y.,
Lane, J. R., Ijzerman, A. P., and Stevens, R. C. (2008) The 2.6 Å crystal
structure of a human A2A adenosine receptor bound to an antagonist.
Science 322, 1211–1217
62. Ahn, K. H., Bertalovitz, A. C.,Mierke, D. F., and Kendall, D. A. (2009) Dual
role of the second extracellular loop of the cannabinoid receptor 1. Ligand
binding and receptor localization.Mol. Pharmacol. 76, 833–842
63. Avlani, V. A., Gregory, K. J., Morton, C. J., Parker, M. W., Sexton, P. M.,
andChristopoulos, A. (2007) Critical role for the second extracellular loop
in the binding of both orthosteric and allosteric G protein-coupled recep-
tor ligands. J. Biol. Chem. 282, 25677–25686
64. Conner, M., Hawtin, S. R., Simms, J., Wootten, D., Lawson, Z., Conner,
A. C., Parslow, R. A., and Wheatley, M. (2007) Systematic analysis of the
entire second extracellular loop of the V(1a) vasopressin receptor. Key
GLP-1R ECL2 Is Critical for Receptor Activation
FEBRUARY 3, 2012•VOLUME 287•NUMBER 6 JOURNAL OF BIOLOGICAL CHEMISTRY 3657
 at A
STO
N
 U
N
IV
ERSITY
 on Septem
ber 5, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
residues, conserved throughout a G-protein-coupled receptor family,
identified. J. Biol. Chem. 282, 17405–17412
65. Scarselli, M., Li, B., Kim, S. K., andWess, J. (2007)Multiple residues in the
second extracellular loop are critical for M3 muscarinic acetylcholine re-
ceptor activation. J. Biol. Chem. 282, 7385–7396
66. Shi, L., and Javitch, J. A. (2004) The second extracellular loop of the dop-
amine D2 receptor lines the binding-site crevice. Proc. Natl. Acad. Sci.
U.S.A. 101, 440–445
67. Ahuja, S., Hornak, V., Yan, E. C., Syrett, N., Goncalves, J. A., Hirshfeld, A.,
Ziliox, M., Sakmar, T. P., Sheves, M., Reeves, P. J., Smith, S. O., and Eilers,
M. (2009) Helix movement is coupled to displacement of the second ex-
tracellular loop in rhodopsin activation. Nat. Struct. Mol. Biol. 16,
168–175
68. abu Alla, S., Quitterer, U., Grigoriev, S., Maidhof, A., Haasemann, M.,
Jarnagin, K., and Mu¨ller-Esterl, W. (1996) Extracellular domains of the
bradykinin B2 receptor involved in ligand binding and agonist sensing
defined by anti-peptide antibodies. J. Biol. Chem. 271, 1748–1755
69. Lebesgue, D., Wallukat, G., Mijares, A., Granier, C., Argibay, J., and Hoe-
beke, J. (1998) An agonist-like monoclonal antibody against the human
2-adrenoceptor. Eur. J. Pharmacol. 348, 123–133
70. Ott, T. R., Troskie, B. E., Roeske, R. W., Illing, N., Flanagan, C. A., and
Millar, R. P. (2002) Two mutations in extracellular loop 2 of the human
GnRH receptor convert an antagonist to an agonist.Mol. Endocrinol. 16,
1079–1088
71. Rasmussen, S. G., Devree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Ko-
bilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., Mathiesen,
J. M., Shah, S. T., Lyons, J. A., Caffrey, M., Gellman, S. H., Steyaert, J.,
Skiniotis, G.,Weis,W. I., Sunahara, R. K., and Kobilka, B. K. (2011) Crystal
structure of the 2 adrenergic receptor-Gs protein complex.Nature 477,
549–555
72. Christopoulos, A., and Kenakin, T. (2002) G protein-coupled receptor
allosterism and complexing. Pharmacol. Rev. 54, 323–374
73. Rosenbaum, D. M., Zhang, C., Lyons, J. A., Holl, R., Aragao, D., Arlow,
D. H., Rasmussen, S. G., Choi, H. J., Devree, B. T., Sunahara, R. K., Chae,
P. S., Gellman, S. H., Dror, R. O., Shaw, D. E., Weis, W. I., Caffrey, M.,
Gmeiner, P., and Kobilka, B. K. (2011) Structure and function of an irre-
versible agonist-(2) adrenoceptor complex. Nature 469, 236–240
74. Rasmussen, S.G., Choi,H. J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S.,
Devree, B. T., Rosenbaum, D. M., Thian, F. S., Kobilka, T. S., Schnapp, A.,
Konetzki, I., Sunahara, R. K., Gellman, S. H., Pautsch, A., Steyaert, J.,Weis,
W. I., and Kobilka, B. K. (2011) Structure of a nanobody-stabilized active
state of the (2) adrenoceptor. Nature 469, 175–180
75. Shimamura, T., Shiroishi, M., Weyand, S., Tsujimoto, H., Winter, G., Ka-
tritch, V., Abagyan, R., Cherezov, V., Liu, W., Han, G. W., Kobayashi, T.,
Stevens, R. C., and Iwata, S. (2011) Structure of the human histamine H1
receptor complex with doxepin. Nature 475, 65–70
76. Wu, B., Chien, E. Y., Mol, C. D., Fenalti, G., Liu,W., Katritch, V., Abagyan,
R., Brooun, A., Wells, P., Bi, F. C., Hamel, D. J., Kuhn, P., Handel, T. M.,
Cherezov, V., and Stevens, R. C. (2010) Structures of the CXCR4 chemo-
kine GPCR with small molecule and cyclic peptide antagonists. Science
330, 1066–1071
77. Mann, R. J., Al-Sabah, S., de Maturana, R. L., Sinfield, J. K., and Donnelly,
D. (2010) Functional coupling of Cys-226 and Cys-296 in the glucagon-
like peptide-1 (GLP-1) receptor indicates a disulfide bond that is close to
the activation pocket. Peptides 31, 2289–2293
78. Montrose-Rafizadeh, C., Yang, H., Rodgers, B. D., Beday, A., Pritchette,
L. A., and Eng, J. (1997) High potency antagonists of the pancreatic gluca-
gon-like peptide-1 receptor. J. Biol. Chem. 272, 21201–21206
79. Mann, R. J., Nasr, N. E., Sinfield, J. K., Paci, E., andDonnelly, D. (2010) The
major determinant of exendin-4/glucagon-like peptide 1 differential affin-
ity at the rat glucagon-like peptide 1 receptor N-terminal domain is a
hydrogen bond from SER-32 of exendin-4. Br. J. Pharmacol. 160,
1973–1984
80. Segrest, J. P., De Loof, H., Dohlman, J. G., Brouillette, C. G., and Anan-
tharamaiah, G. M. (1990) Amphipathic helix motif. Classes and proper-
ties. Proteins 8, 103–117
GLP-1R ECL2 Is Critical for Receptor Activation
3658 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 6•FEBRUARY 3, 2012
 at A
STO
N
 U
N
IV
ERSITY
 on Septem
ber 5, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Christopoulos and Patrick M. Sexton
Cassandra Koole, Denise Wootten, John Simms, Laurence J. Miller, Arthur
Has a Critical Role in GLP-1 Peptide Binding and Receptor Activation
Second Extracellular Loop of Human Glucagon-like Peptide-1 Receptor (GLP-1R)
doi: 10.1074/jbc.M111.309328 originally published online December 6, 2011
2012, 287:3642-3658.J. Biol. Chem. 
  
 10.1074/jbc.M111.309328Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
Supplemental material:
  
 http://www.jbc.org/content/suppl/2011/12/06/M111.309328.DC1
  
 http://www.jbc.org/content/287/6/3642.full.html#ref-list-1
This article cites 80 references, 47 of which can be accessed free at
 at A
STO
N
 U
N
IV
ERSITY
 on Septem
ber 5, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
